Core Viewpoint - The company demonstrates strong confidence in its business operations, particularly in the fields of narcotic drugs and elderly care services, as discussed during a recent offline research meeting with institutional investors. Group 1: Narcotic Drug Development - The company has established a comprehensive product cluster in the narcotic pain relief sector, with a focus on the oxycodone series, which includes both raw materials and formulations [2] - The company is the only domestic pharmaceutical enterprise with an integrated advantage in oxycodone raw material and formulation, supported by 100% self-supply of raw materials and strong cost control [2] - The company disclosed that its oxycodone sustained-release tablets are in the registration review stage, with expected approvals in Q4 2026 for the 40mg version and Q3 2027 for the 10mg version [3] - The company emphasizes a unique self-operated model for promoting oxycodone sustained-release tablets, focusing on academic-driven strategies and digital penetration to enhance market coverage [3] - In the ADHD medication sector, the company utilizes a resin-controlled release microsphere technology to improve dosing precision and enhance efficacy and safety for children [3] Group 2: Elderly Care Business Optimization - The company has made significant progress in optimizing its elderly care business model, focusing on cost reduction and efficiency improvements [4] - The Nalan Garden elderly care project has implemented a three-dimensional pricing model to enhance profit contributions per bed while improving service quality and client structure [4] - The company plans to maintain high occupancy rates in community elderly care services while refining management and service quality [4] - The Taihe Ruiyuan project will launch a "trial stay experience" initiative to address the challenges of high turnover rates among elderly residents, enhancing brand promotion and occupancy conversion [5] - The company aims to adapt to changes in centralized procurement policies by focusing on differentiated products and comprehensive value competition strategies [5]

Group 1: Biopharmaceutical Segment - The biopharmaceutical segment accounts for over 80% of the company's revenue, with the strategic product, hydromorphone injection, showing continuous growth. The company aims to establish the most comprehensive hydromorphone product cluster in China, with several products in the pipeline [1][2]. - The approval timelines for hydromorphone sustained-release tablets (10mg and 40mg) are expected in Q4 2026 and Q3 2027, respectively, while acetaminophen-hydromorphone tablets are anticipated to be approved by Q2 2028 [2]. Group 2: Market Strategies - The marketing strategy for hydromorphone sustained-release tablets focuses on a self-operated model, academic-driven promotion, optimized access, tiered channel strategies, digital penetration, and compliance risk control to enhance market share and coverage [2][4]. - The acetaminophen-hydromorphone tablet market is projected to reach CNY 350-400 million by 2025, with a growth rate of approximately 20%-30%. Public healthcare accounts for over 95% of sales, with limited retail and private hospital contributions [2][3]. Group 3: Elderly Care Business - The company has implemented cost-reduction and efficiency-enhancing measures in its elderly care business, with initial positive results. Key strategies include a three-dimensional pricing model and personalized service systems to improve service value and stabilize occupancy rates [5][6]. - The company plans to maintain high occupancy rates in community projects while enhancing management and service quality. The focus will be on personalized care and service systems to boost customer satisfaction and revenue per bed [7][8]. Group 4: ADHD Medication Development - The core technological barrier for the ADHD medication methylphenidate series is the "resin-controlled release microsphere technology," which allows for precise dosage adjustments and stable drug release over 12 hours, significantly improving efficacy and safety for pediatric patients [9]. Group 5: Competitive Strategies in Drug Procurement - The company’s strategy in response to drug procurement policies includes prioritizing differentiated products, maintaining quality and cost advantages, and adapting to new procurement rules by shifting from a price-centric approach to a comprehensive value competition model [10].

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced the withdrawal of the drug registration application for Acetaminophen and Oxycodone Tablets by its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. to further improve the application materials [1][2]. Group 1: Basic Information - The drug name is Acetaminophen and Oxycodone Tablets, with a registration number of CYHS2404364 and a notification number of 2025L00518 [1]. - The National Medical Products Administration (NMPA) issued a termination notice agreeing to withdraw the registration application based on the applicant's request [1]. Group 2: Reasons for Withdrawal and Future Plans - The decision to withdraw the application was made after careful consideration, with plans to resubmit the application after improving the relevant research [2]. Group 3: Impact on the Company - The project for Acetaminophen and Oxycodone Tablets has seen a total investment of 8.861 million yuan, with 5.5371 million yuan capitalized and 3.3239 million yuan expensed as of the announcement date [3]. - The withdrawal of the drug registration application will not impact the company's current financial status or operating performance [4].

Core Viewpoint - The company Beijing Huasu Pharmaceutical Co., Ltd. has decided to withdraw its drug registration application for Oxycodone and Acetaminophen tablets to further improve the submission materials [1] Group 1: Company Actions - Beijing Huasu received a "Drug Registration Application Termination Notice" from the National Medical Products Administration, agreeing to withdraw the application for Oxycodone and Acetaminophen tablets [1] - The company plans to resubmit the drug registration application after enhancing the relevant research [1] Group 2: Regulatory Context - The withdrawal of the application is not an indication of termination of the project, but rather a step to refine the application process [1]

Core Viewpoint - The company Zhongguancun announced the withdrawal of its drug registration application for Acetaminophen and Oxycodone Tablets to further improve the submission materials, indicating that this is not the end of the project and that a resubmission will occur after necessary research is completed [2] Group 1 - The company Beijing Huasu, a subsidiary of Zhongguancun, received a notice from the National Medical Products Administration regarding the termination of the drug registration application for Acetaminophen and Oxycodone Tablets [2] - The total investment in the Acetaminophen and Oxycodone Tablets project amounts to 8.861 million yuan [2] - The withdrawal of the application will not impact the company's current financial status or operating performance [2]

Group 1 - The company Beijing Huasu Pharmaceutical Co., Ltd. has received a termination notice from the National Medical Products Administration regarding the drug registration application for Oxycodone and Acetaminophen Tablets [1] - The specific formulation of the drug includes 5mg of Oxycodone Hydrochloride and 325mg of Acetaminophen per tablet [1] - The termination notice indicates that the company has agreed to withdraw the drug registration application [1]

Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The company's core business shows stable growth, driven by both R&D and restructuring efforts [8] - In 2024, the company achieved total revenue of 25.435 billion yuan, a year-on-year increase of 3.71%, while the net profit attributable to shareholders was 1.330 billion yuan, a decrease of 37.70% [8] - The company is focusing on core products and accelerating R&D innovation, with over 500 projects in the pipeline, including more than 60 innovative drug projects [8] Financial Performance Summary - Total revenue forecast for 2024 is 25.435 billion yuan, with a projected growth rate of 3.71% [8] - The net profit attributable to shareholders is expected to be 1.330 billion yuan in 2024, with a significant decrease of 37.70% [8] - The earnings per share (EPS) for 2024 is projected at 0.81 yuan, with a P/E ratio of 25.56 [8] - The company’s R&D expenses for 2024 are estimated at 1.471 billion yuan, reflecting a slight increase of 0.59% [8] - The company’s core anesthetic business is expected to grow steadily, with net profit forecasts for 2025 and 2026 adjusted to 2.224 billion yuan and 2.653 billion yuan, respectively [8]